NIH | National Cancer Institute | NCI Wiki  

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

Version 1 Next »

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Kim, Erika (NIH/NCI) [E] X
Toby HechtX
Connie SommersX
Amy Leblanc
X
Igor KuzminX
Warren KibbeX
Matthew BreenX
Michael OlinX



Goals

  • Discuss the next 5 years

Discussion items

ItemWhoNotes
Integrating environmental exposures of human cancer patients with canines

Matthew Breen 

  • Human urothelial cancers with dogs that live in their homes
  • Dog omics that share the same environmental exposure as a human individual with cancer
  • Longitudinal studies across these dogs
  • Having an integrated canine commons at the NCI can be a hub for federal and privately funded studies
  • Signatures of lung cancers of smokers vs. someone exposed to smoke, can be validated using canines
  • Toxic compounds in clothing
Cellular Data (Flow Cytometry, Nano String Data)Michael Olin
  • Raw data from the flow cytometer so that people can generate their own plots
  • How can subsets be looked at
Workshop for Immuno-Oncolgy Data Analytics Erika Kim
  • IO data for humans and canines
Non-Cancer Diseases

Toby


Pharma-specific Focus Group

Amy

  • Certain tools and data
  • Immune landscape
  • Comparative nanostring IO cell landscapes
  • Landscape of IHC, Flow, and tools in specific canine tissues and cell types
  • Pharma needs to see placebo groups and to inspect efficacy signals with a set of retractable biomarkers
  • Pharma is looking for supplemental animal model
  • Jax labs may have some immunological data to submit
  • Dose optimization strategies
  • What does the FDA want to see as they are getting more molecularly targeted agents

Minutes (Not Verbatim)

Toby - We don't have sequencing data for comparing before and after therapy to detect genomic changes

Amy - I think Debbie Knapp has this data showing a transcriptional shift

Toby - There has been a suggestion to go beyond cancer and involve other institutes particularly if they can help with funding. Also the Dog Aging project that looks at normal dogs until end of life and some of them develop tumors and the NCI is willing to co-fund sequencing on these tumors as they arise, we are waiting to hear back from Aging Institute, other thing is investigating environmental exposures in relation to to tumors. Let's derive a list of interesting topic.

Warren - Representing the life trajectory of the dogs, attaching the specimens and data derived from those specimens at the appropriate point in that dog's life. The pre and post- treatment specimens are one example (genomics, proteomics, microbiome). Let's say we have measurements from when the dog is born vs. end of life, how can we represent that data to better understand the trajectory of their lives and also carcinogenesis if applicable. Can we prepare the ICDC for hosting this type of data?

Toby - ICDC is a node in the CRDC so not sure non-cancer data is relevant. Aging and NEHES are the closest partners to us to focus on cancer, it will be a stretch to do other things.

Amy - Friend from Bristol Meyers Squib reached out to better understand relationsips with pharma, maybe we should put together a panel of pharma folks to see if they can have a focus group to determine data and tooling would be useful to that community.

Action items

  • Erika to invite Toby and Connie to Immuno-Oncology Workshop


  • No labels